Figure 1: Photograph of agarose gel electrophoresis showing PCR-RFLP of BRCA2 and HOXB13 gene mutation mentioned in Table 1. (A) Here P1, P3, and P4 shows the positive results for BRCA2 gene mutation.
Dr. Daniel P. Petrylak discussed recent developments in prostate cancer care, emphasizing the importance of genetic testing and personalized treatment. Dr. Daniel P. Petrylak, a professor of Medicine ...
Low-Intensity Vibration to Reduce Symptoms and Improve Physical Functioning in Cancer Survivors With Chemotherapy-Induced Peripheral Neuropathy: A Pilot Randomized Trial The following represents ...
Please provide your email address to receive an email when new articles are posted on . Black men with prostate cancer had significantly greater odds of having alterations in immunotherapy targets ...
CLINTON, Wash. — James DeLong was 51 years old and physically fit when he received devastating news in 2001: prostate cancer. "I'm swallowing hard because, you know, I was like, well, in five years, I ...
MiraDx, a molecular diagnostics company focused on germline genetic testing to personalize cancer treatment, announced a new analysis has been published in the Journal of Health Economics and Outcomes ...
Former President Joe Biden announced this weekend that he has been diagnosed with an aggressive form of prostate cancer, the second leading cause of cancer death for men in the United States. About 1 ...
Prostate cancer is one of the most common cancers in men but often goes unnoticed. Experts stress early screening, awareness ...
The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of adults with a deleterious BRCA mutation (germline and/or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback